RECORD // Company

Silexion Therapeutics Corp

Formerly: Biomotion Sciences

Built 2026-11-22T01:26:08Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001178913-26-005201

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-2,533,0003 months ended 2026-09-3010-Q2026-11-120001178913-26-0052012026-11-22 01:26 UTCReport an error
Interest expense$03 months ended 2026-09-3010-Q2026-11-120001178913-26-0052012026-11-22 01:26 UTCReport an error
Cash and cash equivalents$4,760,000at 2026-09-3010-Q2026-11-120001178913-26-0052012026-11-22 01:26 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0002022416
Ticker
SLXN
CUSIP
G1281K130
Record ID
sx:sec:0002022416

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

24 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-19SEC EDGAR company profile2026-11-22 01:26 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-19SEC EDGAR company profile2026-11-22 01:26 UTCReport an error
State of incorporationE92026-11-19SEC EDGAR company profile2026-11-22 01:26 UTCReport an error
Fiscal year end (MMDD)12312026-11-19SEC EDGAR company profile2026-11-22 01:26 UTCReport an error
Business address12 ABBA HILLEL ROAD, RAMAT GAN, L3, 52506062026-11-19SEC EDGAR company profile2026-11-22 01:26 UTCReport an error
ExchangesNasdaq, Nasdaq2026-11-19SEC EDGAR company profile2026-11-22 01:26 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-11,912,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 01:26 UTCReport an error
Total assets (at 2025-12-31)$7,215,0002025-12-3110-K, XBRL Assets2026-11-22 01:26 UTCReport an error
Stockholders' equity (at 2025-12-31)$2,603,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 01:26 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$5,991,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 01:26 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-10,819,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 01:26 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$9,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 01:26 UTCReport an error
Operating lease liabilities (at 2025-12-31)$468,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 01:26 UTCReport an error
Form D total offering amount (D filed 2025-08-11)$3,597,6622025-08-11D2026-11-22 01:26 UTCReport an error
Form D total amount sold (D filed 2025-08-11)$3,597,6622025-08-11D2026-11-22 01:26 UTCReport an error
Form D industry groupBiotechnology2025-08-11D2026-11-22 01:26 UTCReport an error
Form D revenue rangeNo Revenues2025-08-11D2026-11-22 01:26 UTCReport an error
Form D date of first sale2025-08-012025-08-11D2026-11-22 01:26 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-19)Outcome of Nasdaq Hearings Panel; Continued Listing On November 18, 2026, Silexion Therapeutics Corp. (the “Company”) received a favorable decision from a Nasdaq Hearings Panel granting the Company’s request for continued listing on the Nasdaq Capital Market, subject to the conditions described below. The decision followed the Company’s appeal of Nasdaq’s August 18, 2026 delisting determination relating to the Company’s non-compliance with the $2.5 million minimum shareholders’ equity requirement and also addressed the Company’s non-compliance with Nasdaq’s $1.00 minimum bid price requirement. In its final form, the Panel’s decision requires the Company to: (i) by December 4, 2026, complete…2026-11-19SEC EDGAR 8-K 0001178913-26-005294 (text as filed, excerpt)2026-11-22 01:26 UTCReport an error
8-K Item 2.02 (filed 2026-11-16)Results of Operations and Financial Condition. On November 13, 2026, Silexion Therapeutics Corp issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 2.02. The information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act…2026-11-16SEC EDGAR 8-K 0001178913-26-005216 (text as filed, excerpt)2026-11-22 01:26 UTCReport an error
8-K Item 3.03 (filed 2026-11-12)Material Modification to Rights of Security Holders. In connection with its previously-announced 1-for-24 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares (the “Reverse Share Split”) described in Item 5.03 below, on November 11, 2026, Silexion Therapeutics Corp (the “Company”) issued a notice (the “Warrant Adjustment Notice”) to holders of its public warrants and private warrants to purchase the Company’s ordinary shares (the “Warrants”). In the Warrant Adjustment Notice, the Company notified Warrant holders that the Company has made the following adjustments to its outstanding Warrants, effective after the close of trading on November…2026-11-12SEC EDGAR 8-K 0001178913-26-005191 (text as filed, excerpt)2026-11-22 01:26 UTCReport an error
8-K Item 5.03 (filed 2026-11-12)Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As previously reported by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2026, at the extraordinary general meeting of the Company originally held on October 19, 2026 and reconvened on October 26, 2026, the Company’s shareholders approved the Reverse Share Split (as described in Item 3.03 above), at the 1-for-24 ratio determined by the Company’s Board of Directors. On November 10, 2026, the Company’s Board of Directors, acting pursuant to that approval by the Company’s shareholders, effected the Reverse Share Split following the close of trading on the…2026-11-12SEC EDGAR 8-K 0001178913-26-005191 (text as filed, excerpt)2026-11-22 01:26 UTCReport an error
8-K Item 8.01 (filed 2026-11-12)Other Events. The information set forth in Items 3.03 and 5.03 is hereby incorporated by reference into this Item 8.01.2026-11-12SEC EDGAR 8-K 0001178913-26-005191 (text as filed, excerpt)2026-11-22 01:26 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-09)Further to its previous reports, as well as the approval of its shareholders received on October 26, 2026, on November 9, 2026, Silexion Therapeutics Corp, a Cayman Islands exempted company (“Silexion” or the “Company”) issued a press release announcing a prospective 1-for-24 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares. The reverse share split will become effective after the close of the market on November 10, 2026, and the Company’s ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at the open of the market on November 11, 2026. The ticker symbol for the ordinary shares will remain…2026-11-09SEC EDGAR 8-K 0001178913-26-005089 (text as filed, excerpt)2026-11-22 01:26 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.